 |
 |
23rd April 2009
This MeReC Bulletin reviews a number of safety concerns which have emerged relating to inhaled treatments for COPD and sets them into the context of their potential benefits.
The most recent MeReC Bulletin: Recent safety issues with inhaled treatments for COPD (Vol. 19, No. 4) is now available. This is can be read online, and a print-friendly version (pdf) can also be downloaded. Note that we are no longer distributing paper copies of MeReC Bulletins.
The Bulletin discusses:
- the benefits of long-acting bronchodilators and inhaled corticosteroids for patients with COPD
- the safety issues with long-acting beta2 agonists (LABAs) in COPD
- the safety issues with anticholinergics in COPD
- the safety issues with inhaled corticosteroids in COPD
- what needs to be considered when treatment choices are made
MyNPC
To be kept up to date with all MeReC publications, and other NPC news and outputs, make sure you are signed up to NPC Email updates. You can personalise your account, so that you receive information only on what is of interest to you. If you are already signed up and want to amend your details or interests, you can do so at any time.
Feedback
Please comment on this blog in the NPC discussion rooms, or using our feedback form